Partners
We work with our commercial partners to bring innovative and promising biomedical ideas and research to the market. If you are interested to become a Kickstart partner, please contact Dr Rainny Shuyan Xie at rainny.x@nus.edu.sg
Vickers Venture Partners is a venture capital firm focused on angel investments in Asia and beyond.
The firm’s portfolio covers life sciences, technology, media, and telecommunications as well as consumer and financial services. Some of its clients include Baidu.com, Focus Media, Kongzhong Corp, Cambridge Real Estate Investment Trust, Sunfun Info Co., Asian Food Channel, UUCUN, TWG Tea, RTG Asia, and JJE as well as Samumed
Established since 1997, Heritas Capital Management Pte. Ltd (“Heritas”) started out as the investment arm of the IMC Group, a privately owned enterprise with diversified businesses in shipping, lifestyle / real estate and learning / wellness / social entrepreneurship. Since 2013, Heritas has a Capital Markets Services (“CMS”) A/I (Accredited / Institutional) fund management licence, with assets under management exceeding $250m.
Currently, Heritas manages private equity, venture capital and fund-of-funds investments into healthcare, education, and technology globally. Heritas has demonstrated strong hands-on track record of originating, executing and managing investments.
Lightstone Ventures was founded in 2012, when the healthcare teams from Advanced Technology Ventures and Morgenthaler Ventures joined forces, to invest in therapeutic-oriented companies across the life sciences sector. The Lightstone team collectively has over 50 years of experience in the venture capital industry, and nearly 100 years of operational experience including extensive growth company experiences.
Start Codon is a new model of life science and healthcare business accelerator, and the first in Cambridge, UK to provide companies with a combination of seed funding, facilities, mentoring and access to a dedicated team and network of industry leading contacts. Founding investors in Start Codon include Cambridge Innovation Capital, the Babraham Research Campus through Babraham Bioscience Technologies, Genentech, a member of the Roche Group, Dr Jonathan Milner and Dr Ian Tomlinson. Founded to identify ideas that have the potential to impact the diagnosis, prevention and/or treatment of disease, and support their path to successful funding, Start Codon aims to revolutionise the way life science and healthcare innovation is commercialised by reducing risk in investment opportunities and developing companies in the Cambridge, UK cluster that are built to succeed globally.
Milltrust International Group is a specialist investment organisation, co-headquartered in the asset management hubs of London and Singapore, with regional offices in some of the most dynamic markets in the world. Founded in 2011 by an experienced team of institutional investment managers and successful business entrepreneurs including Simon Hopkins, Mark Ebert, Gary Thornton, Alexander Kalis, and Eric Anderson, Milltrust’s investors include pension funds, sovereign entities, family offices, entrepreneurs, and high-net-worth individuals.
Headquartered in Singapore, BioSyngen Group is dedicated in the clinical and commercial transfer of innovative immune-cell therapy technologies and products in Asia and China. The Group has closely research collaborations with world-renowned research institutions, jointly develop innovative technologies and products, receives world exclusive licenses of technologies and products. BioSyngen has a comprehensive and resourceful technical platform to support the development of cell therapy products, such as pre-clinical research, gamma-delta allogeneic cells, development of companion diagnostics, as well as T cell GMP production and clinical trial management.